Immunocore posts Q3 2026 revenue of $102.2 million and announces full enrollment of TEBE‑AM trial
Immunocore Holdings plc reported third‑quarter 2026 net product revenue of $102.2 million, a 1.4% decline from the prior year, and a net loss of $14.2 million ($0.28 per share). The company completed enrollment of 540 patients in the Phase 3 TEBE‑AM trial for previously treated advanced cutaneous melanoma, with topline overall‑survival data expected in the second quarter of 2027. It also dosed the first patient in a Phase 1 trial of its tissue‑specific autoimmune candidate for type 1 diabetes. Cash, cash equivalents and marketable securities stood at $901.3 million at quarter‑end.
Why it matters
The revenue miss and widened loss may pressure the share price, while the strong cash balance provides runway for ongoing trials. The company notes that upcoming Q2 2027 survival data from TEBE‑AM could drive future sales growth.
Key facts
- 1Q3 2026 net product revenue (KIMMTRAK) was $102.2 million, down from $103.7 million in Q3 2025. sec.gov
- 2Net sales for the first nine months of 2026 totaled $324.8 million, compared with $295.5 million in the same period 2025. sec.gov
- 3Underlying revenue growth for Q3 2026 was approximately 10% year‑over‑year after normalising for US wholesaler stocking and an extra sales week in Q3 2025. sec.gov
- 4The Phase 3 TEBE‑AM trial reached its target enrollment of 540 patients. sec.gov
- 5Topline overall‑survival data from the TEBE‑AM trial are expected in Q2 2027. sec.gov
- 6The first patient was dosed in the Phase 1 trial of IMC‑S118AI, the company’s tissue‑specific autoimmune candidate for type 1 diabetes. sec.gov
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.